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ABSTRACT
The aim of this study was to estimate the additional cost of treatment of a group of nosocomial 
infections in a tertiary public hospital. A retrospective observational cohort study was conducted by 
means of analyzing the medical records of 34 patients with infection after total knee arthroplasty, 
diagnosed in 2006 and 2007, who met the criteria for nosocomial infection according to the Centers 
for Disease Control and Prevention. To estimate the direct costs of treatment for these patients, the 
following data were gathered: length of hospital stay, laboratory tests, imaging examinations, and 
surgical procedures performed. Their costs were estimated from the minimum values according to 
the Brazilian Medical Association. The estimated cost of the antibiotics used was also obtained. The 
total length of stay in the ward was 976 days, at a cost of US$ 18,994.63, and, in the intensive care 
unit, it was 34 days at a cost of US$ 5,031.37. Forty-two debridement procedures were performed, 
at a cost of US$ 5,798.06, and 1965 tests (laboratory and imaging) were also performed, at a cost of 
US$ 15,359.25. US$ 20,845.01 was spent on antibiotics and US$ 1,735.16 on vacuum assisted closure 
therapy, microsurgical fl aps, implant removal, spacer use, and surgical revision. The total additional 
cost of these cases of hospital infection in 2006 and 2007 was of US$ 91,843.75. Based on that, we 
demonstrate that the high cost of treatment for hospital infections emphasizes the importance of 
taking measures to prevent and control hospital infection.
Keywords: hospital acquired infection, surgery, costs.
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INTRODUCTION
Nosocomial infections are an important 
problem for healthcare services worldwide.1 
Every year, more than 18 million surgical 
procedures are performed in hospitals in the 
United States and it is estimated that 2.7% 
of these operations become complicated be-
cause of surgical site infection (SSI).2 SSIs 
account for 15 to 30% of all hospital in-
fections3 and are associated with consider-
able morbidity and mortality and increased 
healthcare costs.4 
According to the São Paulo Nosocomial 
Infection Studies and Control Association,5 
it was observed in Brazilian tertiary hospi-
tals in the 1990’s that SSIs were the second 
most frequent type of infection (15.5%) of 
all hospital infections described. During the 
same decade, SSIs occupied the same po-
sition in Spain and Greece, while in Swit-
zerland they were the most prevalent type 
of infection.6 Prevention and control of 
SSIs are very important measures, given 
that such infections increase the length of 
hospital stay, causing additional burden of 
treatment and trouble for patients, such as 
emotional, physical, psychological, social 
and economic distress.7 
Among the types of surgery currently 
performed, implantation of joint prosthe-
ses, particularly those of the hip and knee, is 
increasingly common. It has been estimated 
that 600,000 new hip and knee prostheses 
were implanted only in the United States 
in 2006.8 This type of procedure is subject 
to complications and, among them, infec-
tion is the most difficult to resolve.9 In cases 
of arthroplasties, SSIs are infections that 
may appear up to one year after the surgi-
cal procedure, whenever such infections can 
be correlated with the surgery.10 In a study 
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conducted in England, the prevalence of SSIs was esti-
mated as 0.65%, among 15,792 total knee arthroplasty 
procedures.11
It is important to emphasize that the impact of no-
socomial infections can be estimated through their re-
percussions on morbidity, mortality, and economic 
costs. Studies on the economic impact conducted in the 
United States and Europe have estimated that the cost of 
treatment for these infections is more than US$ 4 billion 
a year.12
Evaluation of healthcare costs may involve three 
components: direct costs (prolongation of hospital stay, 
readmission, surgical procedures, medications, and lab-
oratory tests);12 indirect costs (impaired quality of life, 
loss of productivity, etc.); and expenditure on primary 
healthcare.13 Some studies have quantified the impact 
of SSIs by analyzing the length of hospital stay and the 
direct costs of hospitalization for treatment of these 
infections.3,12 
Hence, our study aimed to estimate the additional 
direct cost of treatment for a group of hospital infec-
tions in a tertiary public hospital in Brazil.
MATERIAL AND METHODS
This study was conducted at the Institute of Orthoped-
ics and Traumatology of Hospital das Clínicas, at the 
School of Medicine of Universidade de São Paulo. This 
is a public tertiary-level teaching hospital with 150 beds. 
Over the study period, an average of 3,000 patients were 
seen per day, and around 500 orthopedic surgical proce-
dures were performed per month.
This was a retrospective observational cohort study 
conducted by means of analyzing the medical records 
of 34 patients who developed infections after total knee 
arthroplasty diagnosed in 2006 and 2007. All patients 
included in this analysis had nosocomial infections re-
lated to the arthroplasty procedure, diagnosed accord-
ing to the criteria of the Centers for Disease Control 
and Prevention (CDC).10 The Hospital Information and 
Management System software was used to search for the 
patients included in this study.
It was obtained the following information from 
each patient’s medical records: age, gender, and preop-
erative risk classification according to the index of the 
American Society of Anesthesiologists. Information on 
readmission for treatment of infections related to the 
implant was also gathered: length of hospital stay, and 
subsidiary tests performed – including laboratory and 
imaging tests –, along with the surgical procedures and 
the antibiotics used.
The costs related to the length of hospital stay, the 
subsidiary examinations and the surgical procedures 
performed were estimated from the values suggested by 
the Brazilian Medical Association for the period of this 
research. The cost of the antibiotics used was obtained 
from the last purchase made by the hospital through a 
tendering procedure. This class of medications was cho-
sen for the analysis because it is usually the most expen-
sive prescription item on this teaching hospital. 
The values obtained in Real, Brazilian currency, were con-
verted into Dollar using the exchange rate of March 2008.
DATA ANALYSIS
The qualitative variables were represented by absolute fre-
quencies (n) and relative frequencies (%), and the quantita-
tive variables, by means and standard deviations (SD).
RESULTS
The patients’ mean age was 67.1 ± 12.0 years. There were 
23 women (67.6%) and 11 men (32.4%). None of the 
patients had a preoperative risk assessment on the ASA 
scale of more than II (Table 1). 
As shown in Table 2, to treat these cases of nosoco-
mial infections required 976 days in hospital wards at 
total cost of US$ 18,994.63, and 34 days in the intensive 
care unit at a cost of US$ 5,031.37. 
Over the study period, 1965 laboratory tests were 
performed, and the most frequent were: creatinine as-
says (157), serum urea assays (146), blood cell counts 
Table 1. Epidemiological and clinical characteristics 
of studied patients
  Characteristics (n = 34)
 Mean age (years) ± SD  67.1 ± 12.0
 Female  67.60%
 Male  32.40%
 ASA* I  26.50%
 ASA II  73.50%
*ASA, American Society of Anesthesiologists’ score.
Table 2. Direct costs attributed to additional length 
of hospital stay to treat hospital infection after total 
knee arthroplasty
 Additional length  Absolute 
Cost (US$)
 
of hospital stay number (days) 
 Length of stay in ward 976 18,994.63 
 Length of stay in 34 5,031.37
 intensive care unit
 Total cost (US$) - 24,026.00
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(146), platelet counts (152), serum sodium assays (135), 
serum potassium assays (137), and microbiological exam-
inations, of which aerobic bacteria culture was the most 
common type (102). The average of the laboratories tests 
performed per patient was of 57.8, thereby generating an 
additional cost of US$ 15,359.24 (Table 3).
Regarding the medications used to treat these infec-
tions, an additional cost of US$ 20,845.01 was estimated 
for the antibiotic therapy. The most used antimicrobial 
drugs were vancomycin and cefepime (Table 4).
Furthermore, 42 additional surgical procedures were re-
quired to treat these nosocomial infection patients. Some of 
these involved surgical debridement, vacuum assisted clo-
sure therapy, microsurgical fl aps, implant removal, use of 
spacer, and two stages revision (Table 5).
The estimated additional cost attributed to these cases of 
hospital infection in 2006 and 2007 was of US$ 91,843.75.
Table 3. The most frequent laboratory tests request-
ed for patients with hospital infection after total 
knee arthroplasty
 Test Quantity
 Unit price Cost (US$)
   (US$)
 Creatinine 157 3.35 525.95
 Urea 146 3.35 489.10
 Hemogram 146 7.19 1,049.74
 Platelets 152 2.40 364.80
 Sodium 135 3.35 452.25
 Potassium 137 3.35 458.95
 Cultures 102 28.75 2,932.50
 Total cost - - 6,273.29
Table 5. Direct costs of laboratory tests and proce-
dures used to treat hospital infections in cases of 
total knee arthroplasty
 Variables Absolute Cost
  number (US$)
 Laboratory tests 1965 15,359.25
 Surgical debridement 42 5,798.06
 Vacuum assisted therapy 5 1,735.16
 Microsurgical flap 2 910.43
 Implant removal with  19 7,283.51
 installation of spacer
 Surgical revision 2 527.09
 Total cost - 31,613.50
Table 4. The most frequent antimicrobial agents 
used in patients with hospital infection after total 
knee arthroplasty
Antimicrobial  Unit price
 Quantity 
 
agents (US$)
 (flasks/ Cost (US$) 
   ampoules)
 Vancomycin 1.79 1408 2,520.32
 Cefepime 2.28 2000 4,560.00
 Teicoplanin 18.14 483 8,761.62
 Imipenem  10.72 240 2,572.80
 + cilastatin
 Ertapenem 90.01 27 2,430.27
 Total - 4158 20,845.01
 
DISCUSSION
The economic impact to manage the infected total knee ar-
throplasty reaches an annual amount of US$ 300 million in 
the United States.9 Moreover, Stone (2005) found that SSIs 
on the hip may increase hospital stay to around 104 days 
and have an additional cost of US$ 95,000.14 Another study 
conducted by Kirkland et al in 199915 quantifi ed the impact 
of the treatments for SSIs on 255 patients. The additional 
direct cost for the management of SSIs was of US$ 5,038.00 
per patient, and the total additional cost stemming from the 
SSIs over the study period was of US$1,974,988.00. Another 
two studies estimated an additional cost per patient of US$ 
5,000.00 for treatment of infected total knee arthroplasty7 
and of US$ 2,867.50 per patient with SSI in general.16
Most studies carried out to evaluate the economic impact 
of SSIs have used length of hospital stay as an indicator for 
the costs required for such infections. In studies conducted 
in different occasions between the 1950’s and the beginning 
of the 1980’s, the additional hospital stay attributed to SSIs 
was estimated to be between seven and 24 days.15 Studies 
conducted more recently have shown that SSIs could pro-
long the hospital stay by seven to 19.5 days, with an esti-
mated cost of about US$ 4,500 per patient.3,12
The use of the direct costs of hospitalization has been 
suggested as the best method to estimate the costs of hos-
pital related infections, since they represent the real costs to 
the hospital for the items and services used by each patient. 
Unfortunately, however, this method may underestimate 
the total expenditure and also underestimate the fi nancial 
and personal impact on the patients themselves (indirect 
costs).15
In accordance with previous studies, our study showed 
that the cost of treatment for SSIs is extremely high. The ad-
ditional direct costs to treat infections of total knee arthro-
plasty were of US$ 91,843.75 as whole, and US$ 2,701.29 
per patient.
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It is important to highlight some aspects in this study. 
The method used did not take into account any assessment 
of indirect costs, and expenditures were surveyed using a da-
tabase that presents the minimum costs for the procedures 
evaluated. Thus, the costs for the treatment of this group 
of nosocomial infections may be even higher than the one 
presented here.
Based on the high cost of the treatment for hospital re-
lated infections demonstrated in the present study, it is im-
portant to point out the relevance of implementing meas-
ures to prevent and control nosocomial infections.
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